The Efficacy and Safety of Non‐Biologic and Biologic Treatments in Palmoplantar Pustular Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta‐Analysis
Australasian Journal of Dermatology · 2025-03 · 66 (2) · 53-60
DOI: 10.1111/ajd.14410 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Australasian Journal of Dermatology, online erschienen am 07.01.2025. Verfasst von Khalid M Alshareef und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Biological Products, Dermatologic Agents, Psoriasis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Palmoplantar pustular psoriasis (PPPP), or palmoplantar pustulosis (PPP), is a type of psoriasis that affects the skin on the palms and soles. It is characterised by dermatosis and small sterile pustules and is considered a significant burden on patients' quality of life, as there is currently no gold standard treatment or cure. This network meta‐analysis (NMA) compares the efficacy and safety of biologic and non‐biologic medications for PPPP and PPP. Medline, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched. The efficacy and safety of all medications were assessed through a frequentist NMA using a random‐effects model. Treatments were ranked using the net rank function, yielding P scores. Fourteen RCTs with 1056 participants were included. Guselkumab 100 mg was the most effective for improving PPPGA scores ( p = 0.72, RR = 1.31, CI: 0.31–5.57). Guselkumab 100 mg was ranked the highest for achieving PPPASI‐75 (RR = 5.4, CI: 1.26–23.2, p = 0.023). Oral cyclosporine 1 mg/kg/day was ranked the highest for PPPASI‐50 (RR = 2.10, CI: 0.65–6.82). Etretinate 1 mg/kg/day had the highest rate of adverse events (RR = 1.78, CI: 0.92–3.44). Secukinumab 300 mg was associated with the highest rate of serious adverse events (RR = 1.58, CI: 0.21–12.02). Based on the P‐scores from our NMA, guselkumab 100 mg was the most effective for PPPGA improvement, guselkumab 100 mg for PPPASI‐75, oral cyclosporine 1 mg/kg/day for PPPASI‐50, etretinate 1 mg/kg/day had the most adverse events, and secukinumab 300 mg was associated with the highest rate of serious adverse events. Trial Registration PROSPERO registration number: CRD42023460842
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
- King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
- Dermatology Consultant, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
- Section Head of Department of Dermatology, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
ORCID-Profile: Khalid M Alshareef
Zitieren
APA
Alshareef, K. M., Abualola, A. H., Shaheen, E. A., Aljuaid, A. A., Alshibi, F., Kalantan, R., Bashrahil, B., Alghowairi, D. H., & Alamri, A. M. (2025). The Efficacy and Safety of Non‐Biologic and Biologic Treatments in Palmoplantar Pustular Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta‐Analysis. Australasian Journal of Dermatology, 66(2), 53-60. https://doi.org/10.1111/ajd.14410
Vancouver
Alshareef KM, Abualola AH, Shaheen EA, Aljuaid AA, Alshibi F, Kalantan R, et al. The Efficacy and Safety of Non‐Biologic and Biologic Treatments in Palmoplantar Pustular Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta‐Analysis. Australasian Journal of Dermatology. 2025;66(2):53-60. doi:10.1111/ajd.14410
BibTeX
@article{Alshareef2025,
author = {Alshareef, Khalid M and Abualola, Amal H and Shaheen, Esraa A and Aljuaid, Abdulaziz A and Alshibi, Faisl and Kalantan, Renad and Bashrahil, Bader and Alghowairi, Dhaifallah H and Alamri, Awadh M},
title = {The Efficacy and Safety of Non‐Biologic and Biologic Treatments in Palmoplantar Pustular Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta‐Analysis},
journal = {Australasian Journal of Dermatology},
year = {2025},
volume = {66},
number = {2},
pages = {53--60},
doi = {10.1111/ajd.14410}
}
EUVIMED